You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Express Scripts
Medtronic
McKesson
Merck

Last Updated: January 18, 2021

DrugPatentWatch Database Preview

REPAGLINIDE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Repaglinide patents expire, and when can generic versions of Repaglinide launch?

Repaglinide is a drug marketed by Actavis Totowa, Aurobindo Pharma Ltd, Boscogen, Casi Pharms Inc, Mylan, Paddock Labs Llc, Sun Pharm Inds Inc, and Lupin Ltd. and is included in eight NDAs.

The generic ingredient in REPAGLINIDE is metformin hydrochloride; repaglinide. There are forty-nine drug master file entries for this compound. Additional details are available on the metformin hydrochloride; repaglinide profile page.

Drug patent expirations by year for REPAGLINIDE
Drug Prices for REPAGLINIDE

See drug prices for REPAGLINIDE

Recent Clinical Trials for REPAGLINIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Texas Diabetes InstitutePhase 4
Kuwait UniversityPhase 4
Dasman Diabetes InstitutePhase 4

See all REPAGLINIDE clinical trials

Pharmacology for REPAGLINIDE
Drug ClassGlinide
Mechanism of ActionPotassium Channel Antagonists
Paragraph IV (Patent) Challenges for REPAGLINIDE
Tradename Dosage Ingredient NDA Submissiondate
PRANDIN TABLET;ORAL repaglinide 020741 2005-02-10

US Patents and Regulatory Information for REPAGLINIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actavis Totowa REPAGLINIDE repaglinide TABLET;ORAL 090008-001 Jan 22, 2014 DISCN No No   Start Trial   Start Trial   Start Trial
Paddock Labs Llc REPAGLINIDE repaglinide TABLET;ORAL 201189-003 Jan 22, 2014 AB RX No No   Start Trial   Start Trial   Start Trial
Boscogen REPAGLINIDE repaglinide TABLET;ORAL 091517-001 Apr 24, 2015 AB RX No No   Start Trial   Start Trial   Start Trial
Aurobindo Pharma Ltd REPAGLINIDE repaglinide TABLET;ORAL 203820-001 Jan 22, 2014 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
McKesson
McKinsey
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.